Treatment‐related adverse effects · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment‐related adverse effects · men with chronic Peyronie's disease (plaques without calcification)
It is very uncertain whether injectional nicardipine changes treatment‐related adverse effects compared with saline (very low certainty).
1 finding from 1 review
Treatment‐related adverse effects · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees)
The review found no eligible studies for this question.
2 findings from 1 review
Treatment‐related adverse effects · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…
It is very uncertain whether potassium paraaminobenzoate changes treatment‐related adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Treatment‐related adverse effects · men with Peyronie's disease (palpable plaque or pain)
1 finding from 1 review
Treatment‐related adverse effects · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment‐related adverse effects · men with Peyronie's disease (palpable plaque or pain)
It is very uncertain whether extracorporeal shock wave treatment (ESWT) changes treatment‐related adverse effects compared with sham (very low certainty).
1 finding from 1 review
Treatment‐related adverse effects · men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees)
1 finding from 1 review
Treatment‐related adverse effects · adults and children with sickle cell disease experiencing neuropathic pain
It is very uncertain whether summary of findings ‐ Pharmacological intervention (pregabalin) changes treatment‐related adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Total treatment‐related adverse effects · solid organ transplant recipients
Extended showed no clear difference in total treatment‐related adverse effects compared with short‐duration valganciclovir (moderate certainty).
1 finding from 1 review
Treatment‐related adverse effects (long‐term) · men with Peyronie's disease (not defined)
1 finding from 1 review
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ total ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 4.67 [1.53, 14.26]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ purpura ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 15
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ regrowth ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.5 [0.27, 8.22]
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ fractional CO2 laser versus TAC ‐ charring ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐… compared with other treatments (very low certainty).
1 finding from 1 review
RR 7
Studies not reported
Very low
Incidence of treatment‐related adverse effects: CO2 laser plus TAC versus cryosurgery plus TAC ‐ atrophy ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects: CO2 laser plus TAC… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.13 [0.7, 1.82]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC versus cryosurgery plus TAC ‐ erythema ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.5 [0.47, 4.78]
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ fractional CO2 laser versus TAC ‐ skin atrophy ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐… compared with other treatments (very low certainty).
1 finding from 1 review
RR 0.33 [0.01, 7.72]
Studies not reported
Very low
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ depigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1 [0.07, 15.12]
Studies not reported
Very low
Incidence and severity of treatment‐related adverse effects ‐ fractional CO2 laser versus TAC ‐ telangectasia ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy changes incidence and severity of treatment‐related adverse effects ‐… compared with other treatments (very low certainty).
1 finding from 1 review
RR 0.2 [0.01, 3.92]
Studies not reported
Very low